Skip to main content

Table 2 Multivariate analysis by virological outcome (VL < 400 copies/ml)

From: An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

Variable

Adjusted OR (95% CI)

P value

Sex

 Female

Reference

.

 Male

0.63 (0.29–1.34)

0.233

Second-line regimen group

 ATV/r

Reference

.

 LPV/r

0.46 (0.20–1.03)

0.060

Age at switch to second-line, per 5 year increase

0.91 (0.76–1.10)

0.332

CD4 count cell/μl, at switch to second-line

0.99 (0.99–1.00)

0.468

Time (months) on first-line therapy

1.00 (0.99–1.02)

0.701

Time (years) after switch to viral load date

1.27 (0.95–1.68)

0.103

  1. Note: Adjusted for matching using propensity scores: